Systemic Scleroderma or Paraneoplastic Syndrome?

1. Pelosof MD, PHD LC, Gerber MD DE. Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment. Mayo Clin Proc. 2010;10.4065/mcp.2010.0099293161920810794Search in Google Scholar

2. Zeineddine N, Khoury L El, Mosak J. Systemic Sclerosis and Malignancy: A Review of Current Data. J Clin Med Res. 2016;10.14740/jocmr2606w497483127540435Search in Google Scholar

3. Krämer A. Metastases in the Absence of a Primary Tumor – Advances in the Diagnosis and Treatment of CUP Syndrome: In reply. Dtsch Aerzteblatt Online. 2009;10.3238/arztebl.2009.0294Search in Google Scholar

4. Szekanecz Z, Szekanecz É, Bakó G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases - A mini-review. Gerontology. 2010.10.1159/00031463420453490Search in Google Scholar

5. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-analysis of cohort studies. Rheumatol (United Kingdom). 2012;10.1093/rheumatology/ker26921900368Search in Google Scholar

6. Racanelli V, Prete M, Minoia C, Favoino E, Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmunity Reviews. 2008.1848692110.1016/j.autrev.2008.02.00118486921Search in Google Scholar

7. Ciołkiewicz M, Domysławska I, Ciołkiewicz A, Klimiuk PA, Kuryliszyn-Moskal A. Coexistence of systemic sclerosis, scleroderma-like syndromes and neoplastic diseases. Polskie Archiwum Medycyny Wewnetrznej. 2008.Search in Google Scholar

8. Madrid FF, Maroun MC. Serologic laboratory findings in malignancy. Rheumatic Disease Clinics of North America. 2011.10.1016/j.rdc.2011.09.006386723422075195Search in Google Scholar

9. Zuber M. Positive antinuclear antibodies in malignancies [3]. Annals of the Rheumatic Diseases. 1992.10.1136/ard.51.4.573-b10047231586268Open DOISearch in Google Scholar

10. Solans-Laqué R, Pérez-Bocanegra C, Salud-Salvia A, Fonollosa-Plá V, Rodrigo MJ, et al. Clinical significance of antinuclear antibodies in malignant diseases: Association with rheumatic and connective tissue paraneoplastic syndromes. Lupus. 2004;10.1191/0961203304lu521oa15119543Search in Google Scholar

11. Wen J, Ouyang H, Yang R, Bo L, Zhang Y, Tang M, et al. Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis. Sci Rep. 2018;10.1038/s41598-018-20167-w578901929379092Search in Google Scholar